Journal of Correctional Health Care - April 2023 - 114

114
PRUETTE ET AL.
References
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J.
A. (1993). Clozapine-induced agranulocytosis-Incidence and risk factors
in the United States. New England Journal of Medicine, 329(3), 162-167.
https://doi.org/10.1056/NEJM199307153290303
Andersen, H. S., Sestoft, D., Lillebæk, T., Gabrielsen, G., Hemmingsen, R., &
Kramp, P. (2000). A longitudinal study of prisoners on remand: Psychiatric
prevalence, incidence and psychopathology in solitary vs. non-solitary
confinement. Acta Psychiatrica Scandinavica, 102(1), 19-25. https://doi
.org/10.1034/j.1600-0447.2000.102001019.x
Appelbaum, K. L., Savageau, J. A., Trestman, R. L., Metzner, J. L., & Baillargeon,
J. (2011). A national survey of self-injurious behavior in American
prisons. Psychiatric Services, 62(3), 285-290. https://doi.org/10.1176/ps.62
.3.pss6203_0285
Arora, S., Geppert, C. M. A., Kalishman, S., Dion, D., Pullara, F., Bjeletich, B.,
Simpson, G., Alverson, D. C., Moore, L. B., Kuhl, D., & Scaletti, J. V. (2007).
Academic health center management of chronic diseases through
knowledge networks: Project ECHO. Academic Medicine, 82(2), 154-160.
https://doi.org/10.1097/ACM.0b013e31802d8f68
Balbuena, L., Mela, M., Wong, S., Gu, D., Adelugba, O., & Tempier, R. (2010).
Does clozapine promote employability and reduce offending among
mentally disordered offenders? Canadian Journal of Psychiatry, 55(1), 50-
56. https://doi.org/10.1177/070674371005500108
Black, D. W., Gunter, T., Allen, J., Blum, N., Arndt, S., Wenman, G., & Sieleni, B.
(2007). Borderline personality disorder in male and female offenders
newly committed to prison. Comprehensive Psychiatry, 48(5), 400-405.
https://doi.org/10.1016/j.comppsych.2007.04.006
Cohen, T. R., Mujica, C. A., Gardner, M. E., Hwang, M., & Karmacharya, R.
(2020). Mental health units in correctional facilities in the United States.
Harvard Review of Psychiatry, 28(4), 255-270. https://doi.org/10.1097/HRP
.0000000000000267
Fazel, S., Hayes, A. J., Bartellas, K., Clerici, M., & Trestman, R. (2016). Mental
health of prisoners: Prevalence, adverse outcomes, and interventions. The
Lancet Psychiatry, 3(9), 871-881. https://doi.org/10.1016/S22150366(16)30142-0
Fortney,
J. C., Pyne, J. M., Turner, E. E., Farris, K. M., Normoyle, T. M., Avery, M.
D., Hilty, D. M., & Unu¨ tzer, J. (2015). Telepsychiatry integration of mental
health services into rural primary care settings. International Review of
Psychiatry, 27(6), 525-539. https://doi.org/10.3109/09540261.2015
.1085838
Kane, J. M., Agid, O., Baldwin, M. L., Howes, O., Lindenmayer, J.-P., Marder, S.,
Olfson, M., Potkin, S. G., & Correll, C. U. (2019). Clinical guidance on the
identification and management of treatment-resistant schizophrenia.
Journal of Clinical Psychiatry, 80(2), 18com12123. https://doi.org/10.4088/
JCP.18com12123
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the
treatment-resistant schizophrenic: A double-blind comparison with
chlorpromazine. Archives ofGeneral Psychiatry, 45(9), 789-796. https://doi
.org/10.1001/archpsyc.1988.01800330013001
Kelly, D. L., Freudenreich, O., Sayer, M. A., & Love, R. C. (2018). Addressing
barriers to clozapine underutilization: A national effort. Psychiatric Services,
69(2), 224-227. https://doi.org/10.1176/appi.ps.201700162
Kraus, M. S., & Keefe, R. S. E. (2007). Cognition as an outcome measure in
schizophrenia. British Journal ofPsychiatry, 191(Suppl. 50). https://doi.org/
10.1192/bjp.191.50.s46
Love, R. C., Kelly, D. L., Freudenreich, O., & Sayer, M. A. (2016). Clozapine
underutilization: Addressing the barriers [Working paper]. National Association
of State Mental Health Program Directors. https://nasmhpd.org/
sites/default/files/Assessment%201_Clozapine%20Underutilization.pdf
Lui, S. S. Y., Yang, T. X., Ng, C. L. Y., Wong, P. T. Y., Wong, J. O. Y., Ettinger, U.,
Cheung, E. F. C., & Chan, R. C. K. (2018). Following instructions in patients
with schizophrenia: The benefits of actions at encoding and recall.
Schizophrenia Bulletin, 44(1), 137-146. https://doi.org/10.1093/schbul/
sbx026
Lynch, T. R., Trost, W. T., Salsman, N., & Linehan, M. M. (2007). Dialectical
behavior therapy for borderline personality disorder. Annual Review of
Clinical Psychology, 3(1), 181-205. https://doi.org/10.1146/annurev
.clinpsy.2.022305.095229
Manuel, J. I., Essock, S. M., Wu, Y., Pangilinan, M., & Stroup, S. (2012). Factors
associated with initiation on clozapine and on other antipsychotics
among Medicaid enrollees. Psychiatric Services, 63(11), 1146-1149.
https://doi.org/10.1176/appi.ps.201100435
Mathis, D., & O'Reilly, K. (2010). Point-of-care INR determination, Coumadin
dosage changes, and use of a historical, self-updating database in a
prison. Journal ofCorrectional Health Care, 16(2), 139-146. https://doi.org/
10.1177/1078345809356536
Mela, M., & Depiang, G. (2016). Clozapine's effect on recidivism among offenders
with mental disorders. Journal of the American Academy of Psychiatry
and the Law, 44(1), 82-90. http://www.ncbi.nlm.nih.gov/pubmed/
26944747
Novartis International AG. (2010). Clozaril [package insert]. Novartis International
AG.
Prins, S. J. (2014). Prevalence of mental illnesses in U.S. state prisons: A
systematic review. Psychiatric Services, 65(7), 862-872. https://doi.org/10
.1176/appi.ps.201300166
Rohde, C., Polcwiartek, C., Correll, C. U., & Nielsen, J. (2018). Real-world effectiveness
of clozapine for borderline personality disorder: Results from
a 2-year mirror-image study. Journal of Personality Disorders, 32(6), 823-
837. https://doi.org/10.1521/PEDI_2017_31_328
Sheitman, B. B., Catlett, T. L., & Zarzar, T. R. (2019). Limited availability and
use of clozapine in state prisons. Psychiatric Services, 70(3), 256. https://doi
.org/10.1176/appi.ps.201800470
Siskind, D., Siskind, V., & Kisely, S. (2017). Clozapine response rates among
people with treatment-resistant schizophrenia: Data from a systematic
review and meta-analysis. Canadian Journal of Psychiatry, 62(11), 772-
777. https://doi.org/10.1177/0706743717718167
Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2014). Geographic
and clinical variation in clozapine use in the United States. Psychiatric
Services, 65(2), 186-192. https://doi.org/10.1176/appi.ps.201300180
Tiihonen, J., Lo¨ nnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen,
A., & Haukka, J. (2009). 11-year follow-up of mortality in patients with
schizophrenia: A population-based cohort study (FIN11 study). The Lancet,
374(9690), 620-627. https://doi.org/10.1016/S0140-6736(09)60742-X
Torrey, E. F., Zdanowicz, M. T., Kennard, A. D., Lamb, H. R., Eslinger, D. F.,
Biasotti, M. C., & Fuller, D. A. (2014). The treatment of persons with mental
illness in prisons and jails: A state survey. Treatment Advocacy Center.
https://www.treatmentadvocacycenter.org/storage/documents/
treatment-behind-bars/treatment-behind-bars.pdf
Velligan, D. I., Carroll, C., Lage, M. J., & Fairman, K. (2015). Outcomes of
Medicaid beneficiaries with schizophrenia receiving clozapine only or
antipsychotic combinations. Psychiatric Services, 66(2), 127-133. https://
doi.org/10.1176/appi.ps.201300085
Wimberley, T., MacCabe, J. H., Laursen, T. M., Sørensen, H. J., Astrup, A.,
Horsdal, H. T., Gasse, C., & Støvring, H. (2017). Mortality and self-harm in
association with clozapine in treatment-resistant schizophrenia. American
Journal of Psychiatry, 174(10), 990-998. https://doi.org/10.1176/appi
.ajp.2017.16091097
Zarzar, T., & McEvoy, J. (2013). Clozapine for self-injurious behavior in individuals
with borderline personality disorder. Therapeutic Advances in
Psychopharmacology, 3(5), 272-274. https://doi.org/10.1177/
2045125313484323
Zarzar, T. R., Catlett, T. L., O'Connell, M. G., Harrelson, B. H., Wilson, V. P.,
Rashad, G. N., Morris, D. B., Williams, J. B., Peebles, S. S., & Sheitman, B. B.
(2019). Clozapine reduces self-injurious behavior in a state prison population.
Journal ofthe American Academy ofPsychiatry and the Law, 47(1),
61-67. https://doi.org/10.29158/JAAPL.003818-19
Zarzar, T. R., Mayo, J. P., Rosen, D. L., Williams, J. B., Catlett, T. L., O'Connell, M. G.,
Rashad, G. N., Reed, J. G., Brown, C. L., Robbins, B. V., Naftel, H. A., & Sheitman,
B. B. (2021). Effect of clozapine on time assigned to restrictive housing in a
state prison population. Journal of the American Academy ofPsychiatry and
the Law, 49(4), 581-589. https://doi.org/10.29158/JAAPL.210011-21
Zarzar, T. R., Rosen, D. L., Mayo, J. P. III, O'Connell, M. G., Catlett, T. L., Reed, J.
G., Williams, J. B., & Sheitman, B. B. (2022). Clozapine reduces recurrent
suicidal and self-injurious behavior in treatment-refractory incarcerated
individuals. Journal of Correctional Health Care, 28(5), 329-335. http://doi
.org/10.1089/jchc.21.02.0014
Journal of Correctional Health Care - April 2023

Table of Contents for the Digital Edition of Journal of Correctional Health Care - April 2023
